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patients achieved the non-clinical target serum concentra-
tion. There was no association between the pertuzumab 
serum concentration and pCR within the range observed in 
this study (20–100 μg/mL) supporting no dose adjustments 
needed for patients with lower exposure.
Conclusions This analysis further supports the lack of DDI 
between the two therapeutic proteins and the appropriate-
ness of the approved fixed non-body-weight-adjusted pertu-
zumab dose in the treatment of neoadjuvant EBC with per-
tuzumab in combination with trastuzumab and docetaxel.
Keywords Pertuzumab · Exposure–response · 
Pharmacokinetics · Early breast cancer · HER2 · 
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Introduction
Pertuzumab (PERJETA®, F. Hoffmann-La Roche, Basel, 
Switzerland) is a recombinant, humanized, immunoglobu-
lin (Ig)G1κ monoclonal antibody, which targets human 
epidermal growth factor receptor 2 (HER2). Pertuzumab 
is the first in a new class of targeted cancer treatments 
called HER2 dimerization inhibitors. Non-clinical data 
indicate that pertuzumab and trastuzumab (Herceptin®, F. 
Hoffmann-La Roche, Basel, Switzerland) bind to distinct 
epitopes on the HER2 without competing with each other 
and have distinct mechanisms for disrupting HER2 signal-
ing [1, 2]. These mechanisms are complementary and result 
in augmented anti-proliferative activity in vitro and in vivo 
when pertuzumab and trastuzumab are given in combina-
tion [3–5]. By binding to the subdomain II of the extracel-
lular domain of HER2, pertuzumab prevents heterodimeri-
zation of HER2 with other members of the HER family 
(HER1, HER3, and HER4). As a result, ligand-activated 
Abstract 
Purpose The NeoSphere trial evaluated pertuzumab in the 
neoadjuvant setting [early breast cancer (EBC)] with path-
ological complete response (pCR) as the primary efficacy 
end point. This analysis of pertuzumab aimed to (1) com-
pare its pharmacokinetics (PK) in patients with EBC ver-
sus advanced cancers, (2) to further evaluate PK drug–drug 
interactions (DDIs) when given in combination with tras-
tuzumab, and (3) to assess the relationship between expo-
sure and efficacy to assess the clinical dosing regimen in 
the EBC patients.
Methods Pertuzumab serum concentration data from 180 
patients in NeoSphere were compared to historical observa-
tions and potential DDI was assessed, by applying simula-
tion techniques using a population PK model. The impact 
of pertuzumab exposure on pCR rate was evaluated using a 
logit response model (n = 88).
Results The observed PK matched the population PK 
model simulations, confirming that the PK in neoadjuvant 
EBC appear to be in agreement with the historical observa-
tions. No evidence of a DDI effect of trastuzumab or doc-
etaxel on pertuzumab was observed supporting the doses 
when given in combination. In NeoSphere >90% of EBC 
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downstream signaling is blocked by pertuzumab. Pertu-
zumab is also capable of activating antibody-dependent 
cell-mediated cytotoxicity (ADCC) similar to trastuzumab 
[6]. Pertuzumab in combination with trastuzumab and doc-
etaxel was shown to significantly improve progression-free 
survival (PFS) and overall survival (OS) in patients with 
first-line metastatic HER2-positive breast cancer, which led 
to its approval [7] in the USA in 2012 and in the European 
Union in 2013 with intravenous dosing at a fixed (non-
weight-based dose) loading dose of 840 mg, followed by 
420 mg on a every three-week (q3w) schedule [7–11]. In 
the pivotal trial, CLEOPATRA, no DDI between pertu-
zumab and trastuzumab and between pertuzumab and doc-
etaxel was detected in a limited number of patients evalu-
ated [12].
NeoSphere, a Phase II, multicenter study spread across 
16 countries for HER2-positive breast cancer patients, was 
conducted to assess the activity of pertuzumab (PERJETA®) 
by comparing the therapeutic effects of the conventional 
combination of trastuzumab (Herceptin®) plus docetaxel 
with the combination of pertuzumab with either docetaxel 
or trastuzumab, or both, in a neoadjuvant setting. This clin-
ical trial was a four-arm study evaluating the efficacy and 
safety of neoadjuvant treatment regimens in female patients 
with locally advanced, inflammatory or early-stage HER2-
positive breast cancer. Before surgery, patients were rand-
omized to receive four cycles of one of the following four 
treatment arms: (A) trastuzumab + docetaxel, (B) trastu-
zumab + docetaxel + pertuzumab, (C) trastuzumab + per-
tuzumab, and (D) pertuzumab + docetaxel. Post-surgery 
patients in arm A, B, and D received three cycles of 5-fluo-
rouracil, epirubicin, and cyclophosphamide (FEC) and 
trastuzumab to complete 1-year treatment (17 cycles in 
total). Patients in arm C received four cycles of docetaxel 
followed by three cycles of FEC and trastuzumab to com-
plete 1-year treatment (21 cycles in total). The primary end 
point was pathological complete response (pCR) evaluated 
after Cycle 4. Pertuzumab increased the pCR response rate 
in patients when used in combination with trastuzumab and 
docetaxel (Table 1) [6]. Overall, in the NeoSphere study, 
a significantly higher proportion of women given neoadju-
vant pertuzumab and trastuzumab plus docetaxel achieved 
pCR in the breast than did those given trastuzumab and 
docetaxel alone, leading to its approval in the USA and 
in the European Union in 2013 and 2015, respectively. 
Although pertuzumab plus docetaxel was efficacious, the 
combination of chemotherapy with both antibodies was 
more active than chemotherapy with either antibody alone 
[9]. A 5-year analysis showed that patients achieving a total 
pCR with all groups combined had a longer PFS compared 
with patients that did not achieve total pCR, thus suggest-
ing that pCR could be an early indicator of long-term out-
come in early-stage HER2-positive breast cancer [13].
The objectives of this analysis were to: (1) compare 
pertuzumab PK between the neoadjuvant population 
(early breast cancer [EBC]) in NeoSphere to a popula-
tion of patients with tumor types including the first-line 
metastatic breast cancer (MBC) population, (2) to further 
explore the potential impact of trastuzumab and docetaxel 
on pertuzumab PK, and (3) perform an exposure–response 
(E–R) analysis to explore whether an E–R trend existed at 
the administered pertuzumab dose to further support selec-
tion of the clinical dosing regimen in the target patient 
population.
Table 1  Covariates and pCR response by treatment group in NeoSphere
Continuous covariates were shown as median (range)
LBW lean body weight; NA not applicable; pCR pathological complete response; No number
a Included 15 predose serum pertuzumab samples (5 in Arm B, 4 in Arm C and 6 in Arm D). Predose samples were not used for the PK analysis
b Asian/Black/Hispanic/White/Mixed/Indian or Alaska native
Treatment group A B C D Total
Trastuzumab + + + −
Docetaxel + + − +
Pertuzumab − + + +
No. of patients 41 49 45 45 180
No. of samples, serum pertuzumaba NA 99 85 89 273
Age (years) 51 (37–74) 50 (28–74) 52 (22–68) 49 (27–70) 50 (22–74)
Race (a/b/h/w/m/i)b 11/0/0/29/1/0 10/1/0/37/0/1 8/0/0/37/0/0 8/1/1/33/1/1 37/2/1/136/2/2
Baseline weight (kg) 64.2 (40.5–102) 61 (45–99.1) 68 (35–104.9) 61.7 (44–90) 63.6 (35–104.9)
LBW (kg) 44.4 (32.2–52.7) 43.8 (36.7–55.5) 45.6 (29.3–55.8) 43.9 (33.5–56.1) 44.6 (29.3–56.1)
Albumin (g/dL) 4.2 (3.6–5) 4.4 (3.1–5) 4.4 (3.6–5) 4.4 (3.8–5.3) 4.4 (3.1–5.3)
SGPT (IU/L) 17 (3–49) 17 (6–72) 18 (5–56) 20 (11–43) 18 (3–72)
pCR (NA/No/Yes) 2/30/9 0/24/25 4/35/6 1/35/9 7/124/49
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Materials and methods
Data included in the analysis
Pertuzumab serum concentrations were assessed in this 
study using optional biomarker sample repository (BSR; 
voluntary consented samples) blood samples collected on 
Days 14–21 (window of collection requested) post-dose on 
Cycles 2 and 4, based on the informed consent form (ICF). 
The trial was conducted in full accordance with the guide-
lines for Good Clinical Practice and the Declaration of Hel-
sinki and met local institutional requirements and standards 
for clinical research. All patients provided written informed 
consent. Details of the study design of the NeoSphere trial 
have been described [6]. All NeoSphere patients who had 
pertuzumab serum concentration data available during 
Cycle 2 and/or Cycle 4 were included in the PK analysis, 
and all patients with available pertuzumab serum concen-
tration data from Cycle 2 and/or Cycle 4 as well as pCR 
assessments from Cycle 4 were included in the exposure–
response analysis. BSR blood samples were obtained 
from 180 patients: Arm A, n = 41; Arm B, n = 49; Arm 
C, n = 45; and Arm D, n = 45; patients in Arm A by 
design did not receive pertuzumab treatment. A validated 
enzyme-linked immunosorbent assay (ELISA) that allowed 
the quantification of pertuzumab in the presence of tras-
tuzumab was used for the analysis of the samples in this 
study [12]. The minimum quantifiable serum concentration 
in human serum was 0.150 μg/mL for pertuzumab.
Pharmacokinetic analysis
The pertuzumab serum concentration data collected in 
NeoSphere were analyzed using the published pertuzumab 
population PK model [14]. In this population PK model, 
pertuzumab PK was described by a two-compartment lin-
ear model with a clearance (CL), central volume of distri-
bution (Vc), and terminal elimination half-life of 0.235 L/
day, 3.11 L, and 18 days, respectively. Lean body weight 
(LBW) and baseline serum albumin concentration were 
identified as statistically significant covariates influencing 
pertuzumab PK.
To assess the agreement of the observed PK data in 
NeoSphere with the historical PK data based on the pop-
ulation PK model, a visual predictive check (VPC) and 
numerical predictive check (NPC) were performed. In the 
VPC, a total of 1000 trial replicates were simulated using 
the observed covariates (LBW and baseline albumin) and 
dose regimens for each patient, the model parameter esti-
mates, and simulated patient-specific random effects. In the 
NPC, 1000 replicates were simulated for each patient using 
patient-specific covariates, dose regimens, and random 
inter-individual variability.
PK DDIs between pertuzumab and trastuzumab together 
with the docetaxel effect on pertuzumab PK were exam-
ined by comparing pertuzumab Ctrough as well as individual 
PK parameters between different treatment groups. Pertu-
zumab individual PK parameters (i.e., empirical Bayesian 
estimates, EBEs) of the NeoSphere patients were gener-
ated using the population PK model. Analysis of variance 
(ANOVA) was used to compare PK parameters among dif-
ferent treatment groups, using a p value <0.01 as criteria of 
significance.
Exposure–response analysis
The exposure–response relationship was evaluated 
between Ctrough serum pertuzumab concentrations and pCR 
response. Observed and model-predicted serum Ctrough 
at Cycle 2 were used as a measure of exposure as more 
patients had observed PK measurements in that cycle com-
pared to Cycle 4. Given that samples for pertuzumab PK 
were collected between Days 14 and 21 post-dose, model-
predicted Cycle 2 Ctrough provided less variable results and 
therefore were used for the primary analysis.
The impact of pertuzumab exposure on pCR response 
was evaluated using a logit response model with a linear 
drug effect model according to:
 where E0 is the pCR rate of the control group (Arm A) and 
Slope is the linear drug effect parameter. A slope that is 
significantly (p < 0.05) different from zero based on a log-
likelihood ratio criterion would suggest a change of pCR 
response rate with exposure.
Software
All data preparation, graphical presentations, and expo-
sure–response analysis were performed using S-PLUS soft-
ware, version 6.2 (TIBCO Software Inc., Palo Alto, CA). 
All PK analyses were implemented using NONMEM, ver-
sion 7.1 (ICON Development Solutions, Hanover, MD).
Results
In total, there were 180 patients with a BSR blood sample 
collected; 139 in the pertuzumab-containing arms (Arms 
B, C, and D) and 41 in the trastuzumab plus docetaxel arm 
(Arm A). Of the 180 patients, 173 had Cycle 4 pCR assess-
ments available.
Log(P/(1− P)) = E0 + Slope× Ctrough
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Pertuzumab pharmacokinetic analysis
The pertuzumab Cycle 2 mean observed serum Ctrough was 
70 µg/mL with 98% (130 of 133) of patients in Arms B, 
C, and D achieving the PK target serum Ctrough of > 20 µg/
mL a PK target identified historically based on non-clin-
ical data. The individual model-predicted mean Ctrough 
at Cycle 2 was 60 µg/mL with 97% (130 of 134) of the 
patients achieving a predicted Ctrough serum concentration 
of >20 µg/mL.
The observed pertuzumab serum concentrations in 
NeoSphere matched the covariate-adjusted population 
PK model simulations as assessed by the VPC and NPC, 
demonstrating that the PK data in NeoSphere patients are 
comparable with PK data observed previously in patients 
with various metastatic solid tumors. The inter-individual 
variability of pertuzumab individual pharmacokinetic 
parameters by treatment groups is represented in Online 
Resource 1. NeoSphere patients had a slightly lower 
median LBW (44.6 vs. 49.2 kg) and a higher median serum 
albumin (4.4 vs. 3.9 g/dL) compared to the population used 
to build the pertuzumab population PK model and thus 
needs to be accounted for when comparing the PK. The 
VPC results are shown in Fig. 1, where the observed per-
tuzumab data (circles) in NeoSphere fall within the covar-
iate-adjusted simulated pertuzumab concentrations for the 
historical population (thin lines) for each treatment arm. 
Overall, NPC suggests that the observed NeoSphere PK 
percentiles are in line the corresponding percentiles of the 
historical data as predicted by the model (95.7, 79.1, 39.9, 
14.3, 5.0% for the 95, 75, 50, 25, 5th simulated percentile). 
The slight deviation in NPC can be attributable to the small 

























































Fig. 1  Observed versus simulated pertuzumab serum concentrations 
by treatment group. The dashed lines represent 97.5th and 2.5th per-
centiles based on simulations by the population PK model and the 
observed lean body weight and albumin distributions in NeoSphere. 
The solid lines are the population PK model predictions for a patient 
with the median values of lean body weight and albumin for each 
treatment group. The open circles represent Ctrough serum concentra-
tions observed for NeoSphere patients
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sample size. The individual-predicted Ctrough serum concen-
trations were well correlated with the observed Ctrough, sup-
porting the use of model-predicted Ctrough for DDI and ER 
assessment.
PK DDIs between pertuzumab and trastuzumab 
together with the docetaxel effect on pertuzumab were 
assessed by comparing model-predicted Ctrough serum 
concentrations at Cycles 2 and 4 as well as individual 
model-predicted pertuzumab PK parameters of Neo-
Sphere patients in the different treatment groups. As 
shown in Fig. 2, the model-predicted Ctrough concentra-
tions appear similar across treatment groups, which were 
confirmed by ANOVA at either Cycle 2; p = 0.232 or 
Cycle 4; p = 0.039. The same analysis was performed 
using observed Ctrough concentrations and yielded con-
sistent results (Cycle 2, p = 0.458; Cycle 4, p = 0.033), 
Online Resource 2.
The individual model-predicted pertuzumab PK param-
eters did not appear to differ between patients with or 
without trastuzumab as observed in Fig. 3. An ANOVA 
test confirmed that pertuzumab CL and Vc values were 
similar between patients with or without trastuzumab 
(p = 0.264 for CL and p = 0.956 for Vc, comparing 
Arms B and D) and patients with or without docetaxel 
(p = 0.016 for CL and p = 0.823 for Vc, comparing Arms 
B and C). Collectively the analyses showed no evidence 
of a DDI effect of trastuzumab on pertuzumab PK or of 
docetaxel in the presence of trastuzumab on pertuzumab 
PK.
Exposure–response (ER) analysis
The ER population consisted of 173 patients that had both 
PK and pCR assessments available. Eighty-eight (88) 
patients from treatment groups A and B with week 4 pCR 
assessments were used in the ER analysis of pertuzumab. 
In each treatment group, the pCR rates of patients with PK 
results were similar to those of the overall treated patients 
for each arm of the study [6].
The pCR rate versus the model-predicted pertuzumab 
Ctrough serum concentrations at Cycle 2 are illustrated in 
Fig. 4. The patients included in the plot comprised of two 
groups: Arm A treated with trastuzumab + docetaxel and 
Arm B treated with trastuzumab + docetaxel + pertu-
zumab combined together for the analysis. The model-
predicted pertuzumab Ctrough serum concentrations ranged 
from 3.4 to 103.2 μg/mL. Forty-six of 49 (94%) patients 
treated with pertuzumab (Arm B) had a predicted Ctrough 
pertuzumab serum concentration of >20 μg/mL, the target 
efficacious exposure based on non-clinical efficacy models.
The pCR rate was higher in patients treated with per-
tuzumab plus trastuzumab and docetaxel compared with 
patient treated with trastuzumab and docetaxel (p < 0.05); 
however, there was no significant impact (p = 0.996) on 
the probability of pCR response with an increase in per-
tuzumab serum concentration (Ctrough) beyond 20 μg/mL 
(Fig. 4, panel A). An analysis using observed pertuzumab 
concentrations collected during Days 14–21 of Cycle 2 
yielded very similar results (Online Resource 3).
Fig. 2  Predicted pertuzumab Ctrough serum concentrations at Cycles 
2 and 4. The circles represent predicted Ctrough serum concentrations 
of individual patients, and the squares represent the mean value of the 
group. The short lines represent Ctrough for a patient with the median 
values of lean body weight and albumin for each treatment group
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Discussion
The NeoSphere clinical trial was a four-arm study con-
ducted to assess the activity of pertuzumab in neoadjuvant 
(EBC) setting with pCR as the primary efficacy end point 
(Table 1). In the NeoSphere study, a significantly higher 
proportion of women given neoadjuvant pertuzumab and 
trastuzumab plus docetaxel achieved pCR in the breast than 
did those given trastuzumab and docetaxel alone, with pCR 
rates of approximately 46% and 30%, respectively [6, 13]. 
The objectives of this analysis were to compare pertuzumab 
PK between the EBC population (neoadjuvant treatment) in 
NeoSphere and a population of patients with other tumor 
types including the first-line MBC population, to explore 
the potential impact of trastuzumab and docetaxel on pertu-
zumab PK, and to assess the relationship between exposure 
(Ctrough) and response (pCR) of pertuzumab (in combina-
tion with trastuzumab and docetaxel) in neoadjuvant treat-
ment of EBC. pCR was selected as the outcome variable 
in our E–R analysis as it was the primary end point in the 
trial, later analyses showed a correlation between pCR and 
DFS/EFS, further supporting the utility of pCR as an end 
point. In the NeoSphere trial, the safety and tolerability of 
the triple regimen of pertuzumab, trastuzumab, and doc-
etaxel were similar to those of trastuzumab plus docetaxel 
[15] and no unique safety signals were identified that could 
be attributed to pertuzumab exposure. Therefore, an ER 
analysis with respect to safety was not conducted.
As expected due to differences in demographics (100% 
females versus 62% females) and health status (EBC ver-
sus advanced solid tumors), the patients enrolled in the 





































































Fig. 3  Pertuzumab individual pharmacokinetic parameters by treat-
ment group. The circles represent pharmacokinetic parameters of 
individual patients, and the squares represent the mean value of the 
group. The short lines represent the parameters for a patient with the 
median values of lean body weight and albumin for each treatment 
group
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were lower and higher, respectively, compared to the pop-
ulation PK model population, resulting in CL values that 
were slightly lower compared to the reference model. The 
PK model predictions of pertuzumab serum concentrations 
matched the observed serum concentrations after correct-
ing for these baselines covariate differences. Pertuzumab 
PK in the EBC population in NeoSphere appear to be in 
agreement with the PK in patients with other tumor types, 
including the first-line MBC population, when adjusted for 
these characteristics.
The potential impact of trastuzumab or docetaxel on 
the pharmacokinetics of the pertuzumab was examined by 
comparing the individual model-predicted and observed 
Ctrough and model-predicted PK parameters of pertuzumab 
among different treatment groups. The analyses showed 
that there was no evidence of impact of trastuzumab or 
of docetaxel in the presence of trastuzumab on the PK of 
pertuzumab. These results were not surprising since per-
tuzumab and trastuzumab are known to recognize differ-
ent epitopes on the HER2 extracellular domain and do not 
compete for the same binding site [2, 16, 17]. Moreover, 
monoclonal antibodies (mAbs) and small molecules such 
as docetaxel are largely eliminated by distinct routes. Doc-
etaxel is mainly metabolized by hepatic cytochrome P450 
isoenzymes [18, 19], whereas mAbs are primarily elimi-
nated through large-capacity, non-specific, Fc receptor-
mediated IgG clearance mechanisms and through specific, 
target-mediated drug disposition pathways [20]. Addi-
tionally, these results are consistent with the results of a 
previous study that showed no DDI between pertuzumab 
and docetaxel and between pertuzumab and trastuzumab in 
the first-line MBC setting [12].
The pertuzumab clinical dosing regimen of a 840 mg 
fixed loading dose followed by 420 mg every three weeks 
was selected based on PK and safety data from studies 
where pertuzumab was administered as a single agent to 
patients with advanced refractory solid tumors, includ-
ing ovarian cancer, metastatic breast cancer (low HER2 
expressing), and hormone-refractory prostate cancer. 
Results from these clinical studies, from population phar-
macokinetic analyses [21], and from dose–response studies 
in non-clinical xenograft models were used to determine 
the dose of pertuzumab used in late-stage clinical stud-
ies. In single ascending dose studies utilizing pertuzumab 
doses of 0.5–25 mg/kg [22, 23] and also in Phase II studies 
where patients were treated with either 420 mg q3w (fol-
lowing a loading dose of 840 mg) or 1050 mg q3w (with 
no initial loading dose) as a single agent or in combination 
with other chemotherapeutic agents, the maximum toler-
ated dose (MTD) was not reached and no clear dose–safety 
or dose–efficacy relationship was observed. In oncology, 
especially for chemotherapeutic agents, the MTD is often 
carried forward into Phase III studies. However, given 
that pertuzumab is a targeted monoclonal antibody and 
the MTD was not reached, the dose for Phase III studies 
was selected based on achievement of the clinical target 
pertuzumab concentrations (steady-state Ctrough concen-
tration of ≥20 µg/mL in 90% of patients) that resulted in 
maximal suppression of tumor growth in non-clinical xeno-
graft dose–response studies [24]. In the NeoSphere study, 
the majority of patients (>90%) achieved the target serum 
concentrations. Consistent with the non-clinical xenograft 
studies, the ER analysis suggested that there was no asso-
ciation between pCR rate and pertuzumab concentrations 
within the observed concentration range of approximately 
20–100 μg/mL, supporting no dose adjustments needed for 
patient with lower exposure. This analysis further supports 
the appropriateness of the fixed, non-weight-based pertu-
zumab dose of 840 mg followed by 420 mg q3w in the neo-
adjuvant treatment of early breast cancer patients.
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Fig. 4  pCR response rate versus pertuzumab predicted Ctrough 
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[2 × √(p×(1 − p)/n)]. The open circles represent the response status 
of individual patients (0% = non-responder, 100% = responder)
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